Trial · NCT04626024
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
NCT04626024, Phase 2, Active not recruiting, Baylor College of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population. Trials, record NCT04626024. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04626024
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
- NCT number
- NCT04626024
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 17 participants, actual
- Lead sponsor
- Baylor College of Medicine
- Conditions
- Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission
- Interventions
- Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal, Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
- First posted
- 2020-11-12
- Last updated
- 2026-05-04
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Molecular relapse (MR) free survival | From date of TKI cessation to the date of MR or censoring, assessed up to 6 months | The Kaplan-Meier method will be used to estimate MR free survival rate at 6 months after TKI cessation with a 95% confidence interval. |
| Secondary | ddPCR of BCR-ABL1 values affecting MR free survival | At baseline (just before TKI cessation begins) | ddPCR of BCR-ABL1 values (copies/μl) at baseline (just before TKI cessation begins) will be assessed by Cox proportional hazard regression model. |
| Secondary | Event free survival (EFS) | From date of TKI cessation to the date of the event defined or censoring, assessed at 6 months and up to 24 months | The event for EFS is defined as any of the following events: (i) loss of complete hematologic response (CHR), (ii) to accelerated phase or blast crisis (AP/BC), (iii) death due to any cause, whichever occurs first.The Kaplan-Meier method will be used to estimate EFS at 6months and up to 24 months after TKI cessation with a 95% confidence interval. |
| Secondary | Progression-free survival (PFS) | From date of TKI cessation to the date of the progression defined or censoring, assessed at 6 months and up to 24 months | The event of progression is defined by AP/BC or death due to any causes, whichever occurs first. The Kaplan-Meier method will be used to estimate PFS at 6 months and up to 24 months after TKI cessation with a 95% confidence interval. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04626024
GET https://conductscience.org/api/trials/v1/NCT04626024/registered